Studies have indicated that the co-delivery of chemotherapeutic drugs using uPAR-targeted nanoparticles enhanced the therapeutic efficacy in triple negative breast cancer and pancreatic cancer animal tumor models. This evidence concerns the gene PLAUR and neoplasm.